Regentis Biomaterials Ltd. (RGNT)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Regentis Biomaterials Ltd. (RGNT) trades at $3.93. Regentis Biomaterials Ltd. is a regenerative medicine company focused on developing and commercializing tissue repair solutions. Market cap: $15.47M, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026RGNT stock analysis for 2026: Analysts have set a consensus price target of $10.00 for Regentis Biomaterials Ltd., suggesting 154.5% upside from the current price of $3.93. The AI MoonshotScore is 0/100, indicating a strong bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
RGNT: 1/1 perspectives are bearish.
How is this calculated? →Regentis Biomaterials Ltd. (RGNT) Healthcare & Pipeline Overview
Regentis Biomaterials Ltd. develops regenerative medicine solutions, primarily focusing on its Gelrin platform for orthopedic treatments. Their lead product, GelrinC, addresses articular knee cartilage damage. With a market cap of $15.47M, the company operates in the competitive medical instruments and supplies sector, emphasizing tissue repair and regeneration.
What Is the Investment Thesis for RGNT?
Regentis Biomaterials Ltd. presents a focused investment opportunity within the regenerative medicine sector, primarily driven by its GelrinC technology for knee cartilage repair. The company's potential lies in capturing a share of the orthopedic treatment market, estimated to grow significantly due to an aging population and increasing sports-related injuries. A key value driver is the successful commercialization and adoption of GelrinC, contingent on positive clinical trial outcomes and regulatory approvals. The debt-to-equity ratio of 25.23 indicates a moderate level of financial leverage. Upcoming catalysts include clinical trial results for GelrinC and potential partnerships for distribution and market expansion. Potential risks include competition from established players in the orthopedic market and the inherent uncertainties associated with regulatory approvals and clinical trial success.
Based on FMP financials and quantitative analysis
RGNT Key Highlights
- Market capitalization of $15.47M reflects the company's current valuation in the regenerative medicine market.
- Debt-to-equity ratio of 25.23 indicates the company's financial leverage and capital structure.
- Focus on GelrinC, a cell-free hydrogel implant, positions the company in the innovative area of tissue regeneration for knee injuries.
- Operating in the medical instruments and supplies industry, which is experiencing growth due to increasing demand for advanced orthopedic solutions.
- No dividend yield, indicating that the company is currently reinvesting earnings for growth rather than distributing profits to shareholders.
Who Are RGNT's Competitors?
RGNT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ACR ACRES Commercial Realty Corp. | $17.92 | -0.44% | $130.56M | 46 |
| ALF Centurion Acquisition Corp. | $10.89 | +0.00% | $391.36M | 44 |
| ISRG Intuitive Surgical, Inc. | $432.83 | +1.60% | $153.29B | 96 |
| NYXH Nyxoah S.A. | $1.75 | +1.74% | $69.31M | 69 |
| KMTS Kestra Medical Technologies, Ltd. | $27.70 | +2.67% | $1.62B | 67 |
| ZTEK Zentek Ltd. | $0.46 | +2.88% | $49.90M | 63 |
| OMIC Singular Genomics Systems, Inc. | $20.01 | +0.00% | $50.77M | 61 |
| BLMHF Bloom Health Partners Inc. | $0.11 | +0.00% | $5.22M | 51 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RGNT's Key Strengths?
- Proprietary Gelrin technology platform.
- Cell-free, off-the-shelf hydrogel implant (GelrinC).
- Focus on regenerative medicine for orthopedic injuries.
- Potential to improve patient outcomes and quality of life.
What Are RGNT's Weaknesses?
- Limited commercialization experience.
- Dependence on GelrinC for revenue generation.
- Small market capitalization and limited financial resources.
- Competition from established players in the orthopedic market.
What Could Drive RGNT Stock Higher?
- Clinical trial results for GelrinC in new indications.
- Potential regulatory approvals for GelrinC in additional markets.
- Expansion of distribution network through strategic partnerships.
- Continued research and development efforts to enhance the Gelrin platform.
What Are the Key Risks for RGNT?
- Regulatory setbacks or delays in clinical trials.
- Competition from established players in the orthopedic market.
- Product liability claims related to GelrinC.
- Dependence on GelrinC for revenue generation.
- Limited financial resources to support commercialization efforts.
What Are the Growth Opportunities for RGNT?
- Expanding the application of Gelrin technology to other orthopedic indications: Regentis Biomaterials can leverage its Gelrin platform to develop treatments for other orthopedic conditions beyond knee cartilage repair, such as meniscus tears, osteoarthritis, and bone fractures. This expansion would significantly increase the total addressable market, potentially reaching billions of dollars annually. The timeline for this expansion depends on research and development efforts, clinical trials, and regulatory approvals, but could yield new products within the next 3-5 years.
- Securing strategic partnerships for distribution and commercialization: Partnering with established medical device companies or pharmaceutical firms can provide Regentis Biomaterials with access to broader distribution networks, marketing expertise, and sales infrastructure. This would accelerate the commercialization of GelrinC and other products, increasing market penetration and revenue growth. Strategic partnerships could be formed within the next 1-2 years, contingent on successful clinical trial outcomes and regulatory approvals.
- Penetrating international markets beyond the United States and Europe: Expanding into emerging markets such as Asia-Pacific and Latin America can provide Regentis Biomaterials with access to new patient populations and growth opportunities. These markets are experiencing increasing demand for advanced orthopedic treatments due to rising healthcare expenditures and aging populations. Market entry could occur within the next 3-5 years, requiring regulatory approvals and strategic alliances with local partners.
- Developing next-generation Gelrin formulations with enhanced regenerative properties: Investing in research and development to improve the regenerative potential of the Gelrin platform can lead to the creation of more effective and durable treatments. This could involve incorporating growth factors, stem cells, or other bioactive molecules into the hydrogel matrix. Enhanced formulations could be developed and tested within the next 2-3 years, potentially leading to improved clinical outcomes and market differentiation.
- Acquiring complementary technologies or companies to expand the product portfolio: Regentis Biomaterials could acquire companies with complementary technologies or products in the orthopedic space, such as companies specializing in bone grafting materials, joint implants, or rehabilitation devices. This would broaden the company's product portfolio and create synergies in sales, marketing, and distribution. Acquisition opportunities could be pursued within the next 2-3 years, depending on available capital and strategic fit.
What Opportunities Does RGNT Have?
- Expanding the application of Gelrin technology to other orthopedic indications.
- Securing strategic partnerships for distribution and commercialization.
- Penetrating international markets beyond the United States and Europe.
- Developing next-generation Gelrin formulations with enhanced regenerative properties.
What Threats Does RGNT Face?
- Regulatory hurdles and clinical trial risks.
- Competition from established players with greater resources.
- Potential for product liability claims.
- Changes in healthcare reimbursement policies.
What Are RGNT's Competitive Advantages?
- Proprietary Gelrin technology platform.
- Patents protecting GelrinC and related products.
- First-mover advantage in cell-free hydrogel implants for cartilage repair.
- Clinical data supporting the efficacy and safety of GelrinC.
What Does RGNT Do?
Regentis Biomaterials Ltd., established in 2004 and based in Herzliya, Israel, is a regenerative medicine company dedicated to creating tissue repair solutions that improve patient health and quality of life. The company's core technology revolves around its Gelrin platform, which utilizes degradable hydrogel implants designed to regenerate damaged or diseased tissue. Their primary focus is on orthopedic treatments, with a specific emphasis on addressing articular knee cartilage damage. The company's lead product candidate, GelrinC, is a cell-free, off-the-shelf hydrogel that is cured into an implant within the knee. GelrinC aims to provide a solution for painful injuries and cartilage defects. Regentis Biomaterials operates within the broader medical instruments and supplies industry, seeking to innovate in the regenerative medicine space. By developing and commercializing GelrinC, Regentis Biomaterials aims to establish itself as a key player in orthopedic tissue repair, offering an alternative to traditional surgical interventions. The company's strategic focus on regenerative medicine positions it to capitalize on the growing demand for advanced therapies that promote natural healing and tissue regeneration.
What Products and Services Does RGNT Offer?
- Develops tissue repair solutions for orthopedic injuries.
- Focuses on regenerative medicine using hydrogel implants.
- Creates cell-free, off-the-shelf hydrogel implants.
- Offers treatments for articular knee cartilage damage.
- Utilizes the Gelrin platform for tissue regeneration.
- Aims to restore health and enhance patients' quality of life.
How Does RGNT Make Money?
- Develops and patents regenerative medicine technologies.
- Manufactures and sells GelrinC and related products.
- Partners with distributors for market access.
- Generates revenue through product sales to hospitals and clinics.
What Industry Does RGNT Operate In?
Regentis Biomaterials operates within the medical instruments and supplies industry, which is experiencing growth driven by technological advancements in regenerative medicine and increasing demand for minimally invasive orthopedic solutions. The market for cartilage repair is substantial, fueled by an aging population and a rise in sports-related injuries. The competitive landscape includes established players like ISRG (Intuitive Surgical) and ACR (Aclaris Therapeutics), as well as companies specializing in biomaterials and tissue engineering. Regentis Biomaterials aims to differentiate itself through its Gelrin platform and its focus on cell-free hydrogel implants for cartilage regeneration.
Who Are RGNT's Key Customers?
- Hospitals and orthopedic clinics.
- Surgeons specializing in knee and cartilage repair.
- Patients with knee injuries and cartilage damage.
- Distributors of medical devices and implants.
Company Profile
Regentis Biomaterials Ltd. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Herzliya, IL. The company is led by CEO Ehud Geller. RGNT has traded publicly since 2025.
RGNT Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that those closest to the business believe in its potential.
- Community sentiment has shifted positively as discussions around regenerative medicine gain traction, highlighting increased interest in innovative solutions.
- Regentis has made strides in securing partnerships that may enhance its market reach and product development, fostering optimism among investors.
- The recent advancements in clinical trials have bolstered the perception of Regentis as a leader in its niche, attracting attention from both investors and industry experts.
Bear Case
- Concerns over the competitive landscape in the biomaterials sector could dampen enthusiasm, as new entrants may challenge Regentis' market position.
- Social sentiment remains mixed, with some community members expressing skepticism about the scalability of Regentis' technologies in a crowded market.
- Recent regulatory hurdles in the biotech industry have raised questions about the timeline for product approvals, creating uncertainty among investors.
- Market perception may be influenced by broader economic factors affecting the biotech sector, leading to cautious sentiment among potential investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
RGNT Latest News
-
12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga · Jul 1, 2026
-
Regentis Biomaterial Secures Deal to Raise $6.5 Million in Private Placement
MT Newswires · Jun 18, 2026
-
Reported Earlier, Regentis Biomaterials Prices $6.5M Private Placement With Warrants, 1.86M Shares At $3.50 Per Share
benzinga · Jun 18, 2026
-
Regentis Biomaterials Announces Pricing of a $6.5 Million Private Placement
accessnewswire.com · Jun 17, 2026
RGNT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RGNT.
Price Targets
Consensus target: $10.00
RGNT MoonshotScore
What does this score mean?
The MoonshotScore rates RGNT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
12 Health Care Stocks Moving In Wednesday's Intraday Session
Regentis Biomaterial Secures Deal to Raise $6.5 Million in Private Placement
Reported Earlier, Regentis Biomaterials Prices $6.5M Private Placement With Warrants, 1.86M Shares At $3.50 Per Share
Regentis Biomaterials Announces Pricing of a $6.5 Million Private Placement
Leadership: Ehud Geller
CEO
Ehud Geller serves as the Chief Executive Officer of Regentis Biomaterials. His background includes extensive experience in the medical device and biotechnology industries. Prior to joining Regentis, he held leadership positions at various companies focused on developing and commercializing innovative healthcare solutions. His expertise spans strategic planning, product development, and market access. He is known for his ability to drive growth and build strong teams. His academic credentials include advanced degrees in science and business administration.
Track Record: Under Ehud Geller's leadership, Regentis Biomaterials has focused on advancing the clinical development and commercialization of GelrinC. He has overseen the expansion of the company's research and development efforts, as well as the establishment of strategic partnerships. Key milestones during his tenure include securing regulatory approvals for GelrinC in select markets and initiating clinical trials to expand its indications.
What Investors Ask About Regentis Biomaterials Ltd. (RGNT) — Healthcare
What does Regentis Biomaterials Ltd. do?
Regentis Biomaterials Ltd. is a regenerative medicine company focused on developing and commercializing tissue repair solutions for orthopedic injuries. Their primary product, GelrinC, is a cell-free, off-the-shelf hydrogel implant designed to regenerate damaged cartilage in the knee. The company's business model revolves around developing and patenting regenerative medicine technologies, manufacturing and selling GelrinC, and partnering with distributors to reach hospitals, clinics, and surgeons specializing in knee and cartilage repair. Regentis aims to provide innovative solutions that restore health and enhance the quality of life for patients with orthopedic conditions.
What are the main risks for RGNT?
Regentis Biomaterials faces several key risks inherent to the biotechnology and medical device industries. These include the potential for regulatory setbacks or delays in clinical trials, which could impact the timeline for commercializing GelrinC. The company also faces competition from established players in the orthopedic market with greater resources and market presence. Product liability claims related to GelrinC pose another risk, as do changes in healthcare reimbursement policies that could affect the adoption of the company's products. Furthermore, Regentis is dependent on GelrinC for revenue generation, and its limited financial resources could constrain its commercialization efforts.
What are the key factors to evaluate for RGNT?
Evaluate RGNT on fundamentals, analyst consensus, and risk factors. Analysts target $10.00 (+154%). Not financial advice.
How frequently does RGNT data refresh on this page?
RGNT prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven RGNT's recent stock price performance?
Regentis Biomaterials Ltd. (RGNT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary Gelrin technology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RGNT overvalued or undervalued right now?
Valuing Regentis Biomaterials Ltd. (RGNT) requires multiple metrics. Analysts target $10.00 (+154%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying RGNT?
Before investing in Regentis Biomaterials Ltd. (RGNT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding RGNT to a portfolio?
Key strength of Regentis Biomaterials Ltd. (RGNT): Proprietary Gelrin technology platform. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and may be subject to change.
- AI analysis is pending and may provide additional insights.